Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
Hidenori KatoPaul de SouzaSang-We KimJason D LickliterYoichi NaitoKeunchil ParkSanjeev KumarGanesh M MugunduYung-Jue BangPublished in: Targeted oncology (2021)
Adavosertib 175 mg bid for 2.5 days was chosen as the recommended Phase II dose in combination with paclitaxel and carboplatin in Asian patients.